Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imetelstat - Geron Corporation

Next Previous
Drug Profile

Imetelstat - Geron Corporation

Alternative Names: GRN 163-L; GRN-719; GRN163L peptide; Imetelstat sodium - Geron Corporation; JNJ-63935937; RYTELO

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geron Corporation
  • Class Antifibrotics; Antineoplastics; Drug conjugates; Lipids; Oligonucleotides
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelodysplastic syndromes
  • Phase III Myelofibrosis
  • Phase II Acute myeloid leukaemia
  • Discontinued Brain cancer; Breast cancer; Essential thrombocythaemia; Lymphoproliferative disorders; Multiple myeloma; Non-small cell lung cancer; Polycythaemia vera; Solid tumours

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Myelofibrosis(Combination therapy, First-line therapy) in USA (IV, Infusion)
  • 11 Mar 2025 Registered for Myelodysplastic syndromes (Second-line therapy or greater) in Liechtenstein, Norway, Iceland, European Union (IV)
  • 11 Mar 2025 Geron plans to launch imetelstat in Myelodysplastic syndromes in the European Union in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top